Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

BMC Cancer

Table 2 Gene expression datasets used

Dataset	Platform	Source	Patients
			NEPC	AdCa	Ad+NED
Meta-analysis NEPC datasets
LuCaP xeno	Agilent	Internal	3	16
VPC xeno	Agilent	GSE41192	2	6
MDA xeno	Affymetrix 3'	GSE32967	3	2	1
MDA l-CRPC	Agilent	GSE33277	4	16
UM mCRPC	Agilent	GSE35988	2	33
UW mCRPC	Agilent	GSE66187	2	41	4
Other NEPC and prostate datasets
SU2C (mCRPC)	RNA-seq	cBioPortal	5^a	113	*
WCMC (mCRPC)	RNA-seq	cBioPortal	10^a	25	*
TCGA	RNA-seq	cBioPortal		333
JHU-FFPE	Affymetrix Exon	GSE104786	16	16	1
Mayo-FFPE	Affymetrix Exon	GSE61126		235
MSKCC	Affymetrix Exon	GSE21034		150
UW-extra	Agilent	GSE77930	2	39	2
GRID datasets (FFPE)
Prospective	Affymetrix Exon	GenomeDx		2293
JHU-RP	Affymetrix Exon	GSE79958		355
Mayo	Affymetrix Exon	GSE46691		780
		GSE61126

Legend: ^aNEPCs in SU2C and WCMC included adenocarcinomas with NE differentiation, SCPCs, and LCNECs, but without specification of subtype. NEPCs in other datasets were entirely SCPCs except for one LCNEC sample from MDA xeno

ISSN: 1471-2407